Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Jun 09, 2023 7:45pm
176 Views
Post# 35489528

RE:RE:RE:Quentin30 is a pathological prevaricator.

RE:RE:RE:Quentin30 is a pathological prevaricator.how do you know what I hold Noteable ? moron, You have been bleeting multi billion dollar buyout for years here and we're still waiting... and every news release from ONCY is met with share price destruction.. is that not true ???

I grew tired of this happening time after time, as a long term holder... and after holding a 95% loss at one time, have been playing the swings and dips and getting to a zero loss point.

You cannot buy and hold this company. share price rises never have traction. You can tell that no deal is near, because Matt and Co are creating new shares into every rise...

AS I have stated time and time again, only unassailable data or a partnership will change this tired paradigm. The recent data still leaves uncertainty on the table... we don't yet know if bracelet-1 confirms the OS advantage of IND-213... 

so, rather than entice newbies into buying stock, yeah, it's better to inform them of the risk they run, if all they see if your rose tinted view of fairies and rainbows..

What is YOUR agenda..?? constantly pumping, which of us has been right more often ???

It's fr*&^ ing obvious you have an agenda because you post non-stop to the point of nausea, and having been conned by the likes of posters like you into holding this pos, then yeah, I will post what I see as the truth... 

5 years of BS from ONCY to get back to where we were... why no PHASE III ? and again, as I have stated time and again, the FDA did not TELL ONCY to find a biomarker, as per the recent call, they 'suggested' it... so folks caveat emptor, cause if you jump in before this bottoms, then you WILL be holding a loss for 6 months or so.

I would recoomend buying in october... till then it'll be flat without a significant piece of news... don't believe me?... well just wait and see..

glta
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse